View Past PerformanceThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsOrapi バランスシートの健全性財務の健全性 基準チェック /56Orapiの総株主資本は€28.9M 、総負債は€40.2Mで、負債比率は139.2%となります。総資産と総負債はそれぞれ€179.3Mと€150.4Mです。主要情報139.17%負債資本比率€40.20m負債インタレスト・カバレッジ・レシオn/a現金€11.94mエクイティ€28.89m負債合計€150.37m総資産€179.26m財務の健全性に関する最新情報更新なしすべての更新を表示Recent updatesNew Risk • Nov 01New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next year. Trailing 12-month net loss: €27m Forecast net loss in 1 year: €6.5m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable next year (€6.5m net loss next year). Market cap is less than US$100m (€42.1m market cap, or US$45.6m).Buy Or Sell Opportunity • Apr 29Now 27% undervalued after recent price dropOver the last 90 days, the stock has fallen 8.5% to €5.80. The fair value is estimated to be €7.96, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 4.3% over the last 3 years. Meanwhile, the company became loss making.Reported Earnings • Apr 19Full year 2023 earnings released: €2.89 loss per share (vs €0.12 profit in FY 2022)Full year 2023 results: €2.89 loss per share (down from €0.12 profit in FY 2022). Revenue: €229.1m (flat on FY 2022). Net loss: €18.8m (down €19.6m from profit in FY 2022). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 138 percentage points per year, which is a significant difference in performance.New Risk • Apr 08New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Currently unprofitable and not forecast to become profitable next year (€8.8m net loss next year). Market cap is less than US$100m (€42.3m market cap, or US$45.9m).New Risk • Dec 08New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next year. Trailing 12-month net loss: €7.2m Forecast net loss in 1 year: €2.5m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (18% average weekly change). Minor Risks Currently unprofitable and not forecast to become profitable next year (€2.5m net loss next year). Market cap is less than US$100m (€42.0m market cap, or US$45.3m).Valuation Update With 7 Day Price Move • Jun 13Investor sentiment improves as stock rises 15%After last week's 15% share price gain to €4.30, the stock trades at a forward P/E ratio of 8x. Average forward P/E is 12x in the Chemicals industry in Germany. Total loss to shareholders of 6.5% over the past year.Buying Opportunity • Oct 26Now 20% undervalued after recent price dropOver the last 90 days, the stock is down 19%. The fair value is estimated to be €5.19, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Meanwhile, the company has become profitable. For the next 3 years, revenue is forecast to grow by 3.8% per annum. Earnings is also forecast to grow by 55% per annum over the same time period.Buying Opportunity • Oct 11Now 20% undervalued after recent price dropOver the last 90 days, the stock is down 16%. The fair value is estimated to be €5.32, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Meanwhile, the company has become profitable. For the next 3 years, revenue is forecast to grow by 3.8% per annum. Earnings is also forecast to grow by 54% per annum over the same time period.Buying Opportunity • Sep 17Now 20% undervaluedThe stock has been flat over the last 90 days. The fair value is estimated to be €5.68, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Meanwhile, the company has become profitable. For the next 3 years, revenue is forecast to grow by 3.8% per annum. Earnings is also forecast to grow by 52% per annum over the same time period.Reported Earnings • Apr 16Full year 2021 earnings released: EPS: €0.03 (vs €1.70 in FY 2020)Full year 2021 results: EPS: €0.03 (down from €1.70 in FY 2020). Revenue: €226.6m (down 15% from FY 2020). Net income: €195.0k (down 98% from FY 2020). Profit margin: 0.1% (down from 3.4% in FY 2020). The decrease in margin was driven by lower revenue. Over the next year, revenue is forecast to grow 4.6%, compared to a 11% growth forecast for the industry in Germany.Valuation Update With 7 Day Price Move • Mar 17Investor sentiment improved over the past weekAfter last week's 17% share price gain to €5.72, the stock trades at a forward P/E ratio of 47x. Average forward P/E is 10x in the Chemicals industry in Germany. Total loss to shareholders of 43% over the past year.Reported Earnings • Sep 22First half 2021 earnings released: EPS €0.37 (vs €1.92 in 1H 2020)The company reported a poor first half result with weaker earnings, revenues and profit margins. First half 2021 results: Revenue: €117.6m (down 16% from 1H 2020). Net income: €2.46m (down 72% from 1H 2020). Profit margin: 2.1% (down from 6.3% in 1H 2020).Reported Earnings • Apr 17Full year 2020 earnings released: EPS €1.70 (vs €0.64 loss in FY 2019)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: €267.5m (up 11% from FY 2019). Net income: €9.22m (up €12.2m from FY 2019). Profit margin: 3.4% (up from net loss in FY 2019). The move to profitability was driven by higher revenue.財務状況分析短期負債: O4Pの 短期資産 ( €101.6M ) が 短期負債 ( €94.9M ) を超えています。長期負債: O4Pの短期資産 ( €101.6M ) が 長期負債 ( €55.5M ) を上回っています。デット・ツー・エクイティの歴史と分析負債レベル: O4Pの 純負債対資本比率 ( 97.8% ) は 高い と見なされます。負債の削減: O4Pの負債対資本比率は、過去 5 年間で155.6%から139.2%に減少しました。貸借対照表キャッシュ・ランウェイ分析過去に平均して赤字であった企業については、少なくとも1年間のキャッシュ・ランウェイがあるかどうかを評価する。安定したキャッシュランウェイ: 利益は出ていないものの、 O4Pは現在のプラスの フリーキャッシュフロー レベルを維持すれば、3 年以上は十分な キャッシュランウェイ を有しています。キャッシュランウェイの予測: O4Pは利益は出ていませんが、フリーキャッシュフローがプラスであり、年間23.5 % 増加しているため、3 年以上は十分なキャッシュランウェイがあります。健全な企業の発掘7D1Y7D1Y7D1YMaterials 業界の健全な企業。View Dividend企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2024/12/22 13:00終値2024/12/11 00:00収益2024/06/30年間収益2023/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Orapi SA 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。1 アナリスト機関Stephanie LefebvreGilbert Dupont
New Risk • Nov 01New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next year. Trailing 12-month net loss: €27m Forecast net loss in 1 year: €6.5m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable next year (€6.5m net loss next year). Market cap is less than US$100m (€42.1m market cap, or US$45.6m).
Buy Or Sell Opportunity • Apr 29Now 27% undervalued after recent price dropOver the last 90 days, the stock has fallen 8.5% to €5.80. The fair value is estimated to be €7.96, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 4.3% over the last 3 years. Meanwhile, the company became loss making.
Reported Earnings • Apr 19Full year 2023 earnings released: €2.89 loss per share (vs €0.12 profit in FY 2022)Full year 2023 results: €2.89 loss per share (down from €0.12 profit in FY 2022). Revenue: €229.1m (flat on FY 2022). Net loss: €18.8m (down €19.6m from profit in FY 2022). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 138 percentage points per year, which is a significant difference in performance.
New Risk • Apr 08New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Currently unprofitable and not forecast to become profitable next year (€8.8m net loss next year). Market cap is less than US$100m (€42.3m market cap, or US$45.9m).
New Risk • Dec 08New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next year. Trailing 12-month net loss: €7.2m Forecast net loss in 1 year: €2.5m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (18% average weekly change). Minor Risks Currently unprofitable and not forecast to become profitable next year (€2.5m net loss next year). Market cap is less than US$100m (€42.0m market cap, or US$45.3m).
Valuation Update With 7 Day Price Move • Jun 13Investor sentiment improves as stock rises 15%After last week's 15% share price gain to €4.30, the stock trades at a forward P/E ratio of 8x. Average forward P/E is 12x in the Chemicals industry in Germany. Total loss to shareholders of 6.5% over the past year.
Buying Opportunity • Oct 26Now 20% undervalued after recent price dropOver the last 90 days, the stock is down 19%. The fair value is estimated to be €5.19, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Meanwhile, the company has become profitable. For the next 3 years, revenue is forecast to grow by 3.8% per annum. Earnings is also forecast to grow by 55% per annum over the same time period.
Buying Opportunity • Oct 11Now 20% undervalued after recent price dropOver the last 90 days, the stock is down 16%. The fair value is estimated to be €5.32, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Meanwhile, the company has become profitable. For the next 3 years, revenue is forecast to grow by 3.8% per annum. Earnings is also forecast to grow by 54% per annum over the same time period.
Buying Opportunity • Sep 17Now 20% undervaluedThe stock has been flat over the last 90 days. The fair value is estimated to be €5.68, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Meanwhile, the company has become profitable. For the next 3 years, revenue is forecast to grow by 3.8% per annum. Earnings is also forecast to grow by 52% per annum over the same time period.
Reported Earnings • Apr 16Full year 2021 earnings released: EPS: €0.03 (vs €1.70 in FY 2020)Full year 2021 results: EPS: €0.03 (down from €1.70 in FY 2020). Revenue: €226.6m (down 15% from FY 2020). Net income: €195.0k (down 98% from FY 2020). Profit margin: 0.1% (down from 3.4% in FY 2020). The decrease in margin was driven by lower revenue. Over the next year, revenue is forecast to grow 4.6%, compared to a 11% growth forecast for the industry in Germany.
Valuation Update With 7 Day Price Move • Mar 17Investor sentiment improved over the past weekAfter last week's 17% share price gain to €5.72, the stock trades at a forward P/E ratio of 47x. Average forward P/E is 10x in the Chemicals industry in Germany. Total loss to shareholders of 43% over the past year.
Reported Earnings • Sep 22First half 2021 earnings released: EPS €0.37 (vs €1.92 in 1H 2020)The company reported a poor first half result with weaker earnings, revenues and profit margins. First half 2021 results: Revenue: €117.6m (down 16% from 1H 2020). Net income: €2.46m (down 72% from 1H 2020). Profit margin: 2.1% (down from 6.3% in 1H 2020).
Reported Earnings • Apr 17Full year 2020 earnings released: EPS €1.70 (vs €0.64 loss in FY 2019)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: €267.5m (up 11% from FY 2019). Net income: €9.22m (up €12.2m from FY 2019). Profit margin: 3.4% (up from net loss in FY 2019). The move to profitability was driven by higher revenue.